News Search Results
May 28, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
$14 billion. As The Wall Street Journal observed in January 2026, "[f]or context, only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value; the index doesn't include Regencell."At all relevant times, Defendants downplayed the likelihood and severity
More news about: Pomerantz LLP
May 28, 2026, 09:15 ET Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum
presented updated BEAM-302 clinical data at ATS 2026 and announced a pivotal expansion under an FDA-aligned accelerated approval pathway. Sana Biotechnology entered a strategic Mayo Clinic collaboration including a $25 million equity investment. Inside that landscape, Avaí Bio, Inc.
More news about: USA News Group
May 28, 2026, 09:15 ET Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
unlock additional opportunities for non-dilutive funding.About Lunai BioworksLunai Bioworks (NASDAQ: LNAI) is an AI-driven biotechnology company focused on accelerating drug discovery and development across the central nervous system (CNS) and other high-unmet-need areas. Lunai integrates
More news about: Lunai Bioworks Inc.
May 28, 2026, 09:00 ET China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy
accelerate the translation of research into clinical use.About SalvectorsShaoxing Salvectors Biotechnology Ltd.(former name: Shanghai Salvectors Biotechnology Ltd.) is a biotechnology company committed to developing new drugs for solid tumors using its drug delivery platform based on the
More news about: Porton Advanced
May 28, 2026, 09:00 ET SueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC
on June 17, 2025, representing a 48,650% increase. The Wall Street Journal noted in January 2026 that only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value than Regencell.Alleged Operational Disconnects
More news about: SueWallSt.com
May 28, 2026, 09:00 ET ImmunoGenesis Appoints Chief Medical Officer
Dr. Dansky Ullmann joins ImmunoGenesis with more than 30 years of leadership experience spanning biotechnology, pharmaceutical, academic, and government organizations, with deep expertise in oncology drug development, immunotherapy, cell therapy, translational
More news about: Immunogenesis Inc.
May 28, 2026, 08:25 ET Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals, Inc.
May 28, 2026, 08:19 ET Rocket One Accepted into AMD AI Developer Program to Advance Simulation of Next-Generation Nanomagnetic AI Accelerator Architecture for AI, Defense and Space Applications
defense and space systems. The Company is also positioned to pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly
More news about: Rocket One Inc.
May 28, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious
More news about: INOVIO Pharmaceuticals, Inc.
May 28, 2026, 08:00 ET Kalohexis Announces First Patients Dosed in First-in-Human Phase 1 Clinical Trial of 710GO for General Obesity
NORTHBROOK, Ill., May 28, 2026 /PRNewswire/ -- Kalohexis, Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced
More news about: Kalohexis
May 28, 2026, 07:08 ET China-US Dual Filing Success: Porton Advanced's End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors' Innovative Oncolytic Bacteria Therapy
global clients to accelerate the translation of research into clinical use.About SalvectorsShaoxing Salvectors Biotechnology Ltd. is a biotechnology company committed to developing new drugs for solid tumors using its drug delivery platform based on the YB1-v3.0 Salmonella bacteria
More news about: Porton Advanced
May 28, 2026, 07:00 ET Denteric Commences a Phase I Safety Study in Patients with Early Alzheimer's Disease
Denteric is a clinical-stage biotechnology company developing immunotherapeutic approaches to address the underlying biological drivers of chronic inflammatory diseases.About GPV381GPV381
More news about: Denteric
May 28, 2026, 06:45 ET Foundayo and Zepbound now covered for millions of Americans
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 28, 2026, 06:30 ET Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the presentation of one late-breaking and two
More news about: Immunic, Inc.
May 28, 2026, 06:00 ET HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions
SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that it will be officially listed on the
More news about: HanchorBio Inc.
May 28, 2026, 04:21 ET Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable
SHANGHAI, May 28, 2026 /PRNewswire/ -- Moyom Biotechnology announced that its premium regenerative aesthetics product, Aphranel® MagiCCrystal CaHA Filler officially achieved European Union Medical Device Regulation (EU MDR)
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel
May 28, 2026, 03:55 ET Aphranel® MagiCCrystal CaHA Filler Achieves EU MDR Certification as a Premium Regenerative Injectable
SHANGHAI, May 28, 2026 /PRNewswire/ -- Moyom Biotechnology announced that its premium regenerative aesthetics product, Aphranel® MagiCCrystal CaHA Filler officially achieved European Union Medical Device Regulation (EU MDR)
More news about: SHANGHAI MOYOM BIOTECHNOLOGY CO., LTD; Aphranel
May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
address unmet medical needs in this patient population.About Leads BiolabsFounded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Nanjing Leads Biolabs Co., Ltd.
May 27, 2026, 18:15 ET Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
conference, please reach out to your respective representative.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
May 27, 2026, 18:00 ET FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test
May 27, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration
More news about: GENE SOLUTIONS SGP PTE. LTD.
May 27, 2026, 15:00 ET Solu Therapeutics Granted FDA Fast Track Designation for STX-0712 for Treatment of Chronic Myelomonocytic Leukemia
BOSTON, May 27, 2026 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that the U.S.
More news about: Solu Therapeutics
May 27, 2026, 13:44 ET Human Longevity's Launched New Entity Human Life Foundation Models, Inc. and Insilico Medicine Collaborates to Build the First Foundation Model for Longevity Science
foundational AI infrastructure for the emerging longevity economy.About Human Longevity, Inc: Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, artificial intelligence, and multimodal diagnostics to extend human healthspan. Through its flagship
More news about: Human Longevity, Inc.
May 27, 2026, 13:12 ET Food Lyophilisation Equipment Market to Hit USD 1.57 Billion by 2030 -- Wissen Research Identifies Key Growth Drivers and Investment Opportunities
Esquire BiotechFreeze-drying and biotechnology processing equipmentKemolo
More news about: Wissen Research LLC
May 27, 2026, 11:15 ET Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 27, 2026, 10:41 ET HEALEY ALS Platform Trial Regimen I expands to 240 participants
mited.About Neurizon Therapeutics LimitedNeurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment
More news about: Neurizon Therapeutics Limited